In the context of diabetes‐related cardiac injury, PKCβ promotes macrophage polarization and myocardial immune inflammation, contributing to myocardial ischemia–reperfusion injury; targeted inhibition of PKCβ markedly improves myocardial function and reduces infarct size [278]. Here, PRKCB is linked to diabetes mellitus.